It’s a stunning loss for the insurer, which sued the government late last year after its star ratings plummeted for 2025.

A federal judge in Texas on Friday tossed a lawsuit brought by Humana that challenged the U.S. government's reduction in the ...

Humana reaffirms the 2025 adjusted EPS outlook of $16.25 versus the consensus of $16.35. For 2025, Humana expects its insurance segment’s benefit ratio guidance of approximately 90.1-90.5%.

Analysts have recently evaluated Humana and provided 12-month price targets. The average target is $280.75, accompanied by a ...

Humana delivered 60% adjusted EPS growth in the quarter and maintained its 2025 outlook. On an adjusted operating profit basis, medical insurance grew 75%, including a better medical loss ratio of ...

Humana Inc. forecast 2025 profit that fell short of Wall Street’s expectations, as the company said it will invest heavily to improve quality in its Medicare Advantage plans that have been hit ...

Discover insights from Humana's Q1 2025 earnings call: growth in Medicaid, strategic investments in CenterWell, and reaffirmed $16.25 EPS guidance.

However, with elevated medical utilization expected, management only mildly increased its language around its 2024 outlook and set a floor for 2025 results roughly in line with those weak 2024 ...

Humana beat Q1 EPS estimates with $11.58, reaffirmed 2025 guidance, and outlined margin goals despite a drop in Medicare Advantage membership.

Group Medicare Advantage will remain relatively flat, and Medicare stand-alone PDP growth will be approximately 200,000. Humana reaffirms the 2025 adjusted EPS outlook of $16.25 versus the consensus ...

Humana reaffirms the 2025 adjusted EPS outlook of $16.25 versus the consensus of $16.35. For 2025, Humana expects its insurance segment’s benefit ratio guidance of approximately 90.1-90.5%.